EISENMENGER SYNDROME: PATHOPHYSIOLOGY AND MANAGEMENT

Prepared by **Dr. Sidhartha Mullapudi**, DrNB (Cardiology), MD (General Medicine)
Last reviewed: October 2026

I DEFINITION AND CORE PATHOPHYSIOLOGY

- **The Definition:** Eisenmenger Syndrome (ES) is the end-stage clinical phenotype of an untreated, large systemic-to-pulmonary cardiovascular communication—including pre-tricuspid shunts (**Atrial Septal Defect [ASD]**) and post-tricuspid shunts (**Ventricular Septal Defect [VSD], Patent Ductus Arteriosus [PDA], Aortopulmonary Window, or Atrioventricular Septal Defect [AVSD]**).
- **The Vascular Transition:** Chronic exposure of the pulmonary vascular bed to augmented pulmonary blood flow (shear stress) and systemic arterial pressure triggers endothelial dysfunction (imbalance of increased **Endothelin-1 and Thromboxane A2** with reduced **Nitric Oxide and Prostacyclin**), smooth muscle hypertrophy, intimal fibrosis, plexiform lesions, and necrotizing arteritis—culminating in irreversible **Pulmonary Vascular Obstructive Disease (PVOD)** (Heath-Edwards Grades IV to VI).
- **The Hemodynamic Result:** Once **Pulmonary Vascular Resistance (PVR)** approaches or exceeds **Systemic Vascular Resistance (SVR)**, the original left-to-right shunt becomes bidirectional or **reverses to right-to-left (R-to-L)**, producing chronic central or differential cyanosis.

II CLINICAL PRESENTATION AND MULTI-ORGAN INVOLVEMENT

- **Central vs. Differential Cyanosis and Clubbing:** Generalized central cyanosis and digital clubbing occur in intracardiac shunts (VSD, ASD), whereas **differential cyanosis and clubbing** (pink fingers with cyanotic, clubbed toes) is pathognomonic of an **Eisenmenger PDA**, as deoxygenated right ventricular blood shunts into the descending aorta distal to the left subclavian artery.
- **Secondary Erythrocytosis and Hyperviscosity:** Chronic tissue hypoxia upregulates renal **Erythropoietin (EPO)** production, increasing red blood cell mass and hematocrit (often exceeding 60 to 65 percent). Decompensated hyperviscosity manifests as headache, dizziness, tinnitus, visual disturbances, lethargy, and paresthesias.
- **Paradoxical Hemostatic Abnormalities (Bleeding and Thrombosis):**
  - **Bleeding Diathesis:** Driven by thrombocytopenia, abnormal platelet function, depletion of high-molecular-weight **von Willebrand factor** multimers from high vascular shear stress, and impaired hepatic synthesis of vitamin K-dependent clotting factors. Manifests as epistaxis, gingival bleeding, menorrhagia, and life-threatening **hemoptysis** (from rupture of fragile bronchial/aortopulmonary collaterals or pulmonary infarction).
  - **Thrombotic Diathesis:** Driven by sluggish dilated pulmonary arteries, endothelial injury, secondary erythrocytosis, and iron-deficient microcytosis. Up to 20 to 30 percent develop **proximal pulmonary artery in-situ thrombosis**, alongside high risk of **paradoxical cerebral embolism (stroke)** and **brain abscess** (due to right-to-left shunting bypassing the pulmonary capillary phagocytic filter).
  - **Arrhythmias and Sudden Cardiac Death:** Chronic right atrial and right ventricular stretch/fibrosis predispose to **Atrial Flutter**, **Atrial Fibrillation**, intra-atrial reentrant tachycardia, and malignant ventricular arrhythmias.
  - **Renal, Hepatobiliary, and Skeletal Complications:** Hyperuricemia and **clinical gout** result from increased erythroid nucleoprotein turnover combined with reduced renal urate fractional excretion. Chronic glomerular hyperfiltration and hypoxia cause **cyanotic nephropathy** (glomerulomegaly, focal segmental glomerulosclerosis, and proteinuria), while chronic heme breakdown causes **calcium bilirubinate (pigment) gallstones** and periosteal reaction causes **hypertrophic osteoarthropathy**.

III DIAGNOSTIC WORKUP AND HEMODYNAMIC CRITERIA (ESC 2020 / ESC-ERS 2022)

- **Transthoracic and Transesophageal Echocardiography:** Demonstrates the underlying defect with **low-velocity bidirectional or right-to-left shunting** (note: the high-velocity murmur of a VSD or the continuous machinery murmur of a PDA **disappears** once Eisenmenger physiology develops, replaced by a loud palpable P2, pulmonary ejection click, and high-pitched Graham Steell murmur of pulmonary regurgitation), marked RV hypertrophy, and flattened interventricular septum.
- **Right Heart Catheterization (RHC):** Confirms pre-capillary pulmonary hypertension (**mPAP greater than 20 mmHg, PAWP 15 mmHg or less, PVR greater than 2 Wood Units**) with systemic or suprasystemic pulmonary pressures and **net right-to-left or bidirectional shunting (Qp:Qs less than 1.0 to 1.5)**.
- **Operability vs. Inoperability Criteria (2020 ESC ACHD Guidelines):**
  - **Operable (Class I): PVR less than 3 Wood Units (WU)** with Qp:Qs 1.5 or greater.
  - **Borderline (Class IIa / IIb): PVR 3 to less than 5 WU** with Qp:Qs greater than 1.5 (Class IIa for ASD/VSD/PDA).
  - **Inoperable / Eisenmenger (Class III — Harm):** Persistent **PVR of 5 WU or greater** (or indexed PVR greater than 8 WU·m2) despite targeted PAH therapy, or **Qp:Qs less than 1.5**, or resting/exercise arterial desaturation. (Note: Per ESC 2020 guidelines, acute vasodilator testing during RHC is **not** recommended to decide defect closure in adults with PAH-CHD.)

IV EVIDENCE-BASED MANAGEMENT (ESC 2020 ACHD / ESC-ERS 2022 PH GUIDELINES)

A Targeted PAH Pharmacotherapy

- **Endothelin Receptor Antagonists (ERAs — First-Line):**
  - **Bosentan (Class I, Level B):** The landmark double-blind randomized **BREATHE-5 Trial** (*Circulation* 2006) proved that **Bosentan** (62.5 mg BD for 4 weeks, then 125 mg BD) significantly reduced PVR index and improved 6-Minute Walk Distance (by +53.1 meters) in WHO Functional Class III Eisenmenger patients **without worsening systemic arterial oxygen saturation (SpO2)**. Requires monthly hepatic transaminase monitoring.
  - **Macitentan (MAESTRO Trial):** Although the Phase III **MAESTRO Trial** (2019) missed its primary 6MWD endpoint in the overall heterogeneous Eisenmenger cohort (which included Down syndrome), it significantly reduced NT-proBNP and lowered PVR in the hemodynamic substudy, and is widely used due to absence of hepatotoxicity.
  - **Phosphodiesterase-5 (PDE-5) Inhibitors and sGC Stimulators (Class IIa): Sildenafil** (20 mg TID) and **Tadalafil** (20 to 40 mg OD) improve exercise capacity, functional class, and survival in observational registries, and are routinely used in **upfront or sequential combination therapy with an ERA**.
  - **Prostanoids / Prostacyclin Receptor Agonists (Class IIa): Inhaled Iloprost**, **Subcutaneous Treprostinil**, or oral **Selexipag** are preferred for patients remaining in WHO Functional Class III/IV despite oral combination therapy; continuous **intravenous Epoprostenol** is generally avoided unless strictly necessary because central venous catheters carry a high risk of **paradoxical air/thrombus embolism** and **catheter-related sepsis/brain abscess**.

B General Supportive Management and Precautions

- **Pregnancy is Strictly Contraindicated (mWHO Class IV — Class III):** Maternal mortality in Eisenmenger syndrome is **30 to 50 percent** (most deaths occur during delivery or the **first postpartum week** due to acute falls in SVR or thromboembolism), and fetal loss exceeds 40 percent. Reliable contraception (**progestogen-only implants/pills or levonorgestrel IUD**; avoid estrogen-containing contraceptives due to thrombosis risk) is mandatory; notice that Bosentan reduces progesterone efficacy via CYP3A4 induction, requiring barrier backup.
- **Avoidance of SVR Reduction and Dehydration:** Strictly avoid dehydration, systemic arterial vasodilators (CCBs, ACEi/ARBs, alpha-blockers, nitrates), hot baths/saunas, and spinal/epidural anesthesia, as any fall in SVR acutely worsens R-to-L shunting and precipitates fatal hemodynamic collapse.
- **Phlebotomy and Iron Management: Routine therapeutic phlebotomy is strictly contraindicated (Class III)**. Isovolumic phlebotomy (removing 250 to 500 mL of blood with simultaneous equal-volume isotonic saline replacement) is restricted **only** to patients with **moderate-to-severe hyperviscosity symptoms**, **hematocrit greater than 65 percent**, and **confirmed absence of dehydration or iron deficiency**. Iron deficiency must be actively screened (serum ferritin and transferrin saturation) and treated cautiously with oral iron.
- **Anticoagulation Caveat:** Routine oral anticoagulation is **not** recommended in all Eisenmenger patients due to high hemoptysis risk; it is reserved for patients with **atrial fibrillation/flutter**, documented **pulmonary artery thrombosis**, or prior embolic events with low bleeding risk.

Clinical Domain	Guideline Recommendation (ESC 2020 / ESC-ERS 2022)	Key Evidence / Clinical Rationale
Defect Closure in ES	**Class III (Harm):** Strictly contraindicated	Shunt acts as an essential RV decompression "pop-off valve"; closure causes acute RV failure and death
First-Line PAH Therapy	**Class I (Level B): Bosentan** in symptomatic WHO FC III ES	**BREATHE-5 Trial:** Lowered PVRi and improved 6MWD without lowering systemic SpO2
Combination PAH Therapy	**Class IIa (Level C):** PDE-5i (Sildenafil/Tadalafil) + ERA; non-IV prostanoids	Avoids central-line paradoxical embolism and sepsis associated with IV epoprostenol
Routine Phlebotomy	**Class III (Harm):** Contraindicated for asymptomatic high Hct	Induces iron-deficient rigid microcytosis, increasing stroke risk; reserve only for symptomatic Hct >65%
Pregnancy (mWHO IV)	**Class III (Contraindicated):** 30–50% maternal mortality	Use progestogen-only contraception (add barrier if on Bosentan due to CYP3A4 interaction)

V SURGICAL AND INTERVENTIONAL CONSIDERATIONS

- **Strict Contraindication to Shunt Closure (Class III):** Surgical or percutaneous closure of the defect is **strictly contraindicated** once Eisenmenger physiology is established. Although unoperated Eisenmenger patients have markedly better medium-term survival than idiopathic PAH (because the defect unloads the RV and preserves systemic cardiac output), closing the defect converts the patient into severe uncompensated PAH with rapid RV failure.
- **Transplantation: Heart-Lung Transplantation** or **Bilateral Lung Transplantation with concomitant intracardiac defect repair** is the only definitive surgical option for patients failing maximal medical therapy (10-year post-transplant survival is approximately 50 percent).

VI PRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT

- **High Burden of Late-Presenting Shunts:** Delayed childhood detection of large VSDs, PDAs, and ASDs in rural India makes Eisenmenger syndrome a major cause of adult congenital cyanotic heart disease.
- **"Treat-and-Repair" in Borderline (Non-Eisenmenger) PAH-CHD:** While true Eisenmenger syndrome (net R-to-L shunt) must never be closed, borderline patients presenting with elevated PVR (**5 Wood Units or greater**) who still maintain a **net left-to-right shunt (Qp:Qs greater than 1.5)** without resting/exercise desaturation may undergo a 6-month trial of targeted PAH therapy (ERA + PDE-5i) followed by repeat RHC; if PVR drops below 5 WU, **fenestrated closure** may be considered (Class IIb).
- **Iron Deficiency Surveillance:** Because nutritional and parasitic iron deficiency is widespread in India, a hemoglobin of 14 to 15 g/dL in an Eisenmenger patient with SpO2 of 75 percent represents **severe iron-deficient relative anemia**; regular monitoring of **MCV, serum ferritin, and transferrin saturation** with judicious iron repletion prevents hyperviscosity strokes.
- **Air Travel and Non-Cardiac Surgery:** Commercial aircraft cabins are pressurized to an equivalent altitude of 1,800 to 2,400 meters; although most stable Eisenmenger patients tolerate flight if well hydrated, supplemental in-flight oxygen is advised for patients with resting SpO2 below 85 percent or NYHA Class III/IV symptoms, and all non-cardiac surgeries must be performed in tertiary ACHD centers with air-bubble filters on all intravenous lines.

KEY REFERENCES

- **Baumgartner H, De Backer J, Babu-Narayan SV, et al.:** 2020 ESC Guidelines for the management of adult congenital heart disease, *European Heart Journal*, 2020.
- **Galiè N, Beghetti M, Gatzoulis MA, et al. (BREATHE-5 Investigators):** Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study, *Circulation*, 2006.
- **Humbert M, Kovacs G, Hoeper MM, et al.:** 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension, *European Heart Journal*, 2022.